Short answer
Cardiff Oncology, Inc. (CRDF) filed an 8-K current report with the SEC on June 3, 2026 reporting Item 7.01 (Regulation FD Disclosure). Investor presentation reviews Phase 2 CRDF-004 data for onvansertib.
Cardiff Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor presentation reviews Phase 2 CRDF-004 data for onvansertib
- Registrational study plans signal potential transition toward pivotal development
- Exhibit 99.1 contains substantive data and forward-looking statements for investor review
- Disclosure furnished under Regulation FD, not filed under Exchange Act Section 18 liabilities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cardiff Oncology, Inc. 8-K filings
Get the next CRDF 8-K as it lands
Follow CRDF for push alerts, or ask the research agent what this filing means.